Robin Lloyd is a freelance writer, editor and educator, as well as a contributing editor for Scientific American and an adjunct professor at New York University’s Science, Health and Environmental Reporting Program. She has a Ph.D. and M.A. in sociology from the University of California, Santa Barbara, and a B.A. from Smith College. She completed a Knight Science Journalism Fellowship at the Massachusetts Institute of Technology for the 1998-1999 academic year.
Robin Lloyd
Locum News Editor
Spectrum
From this contributor
Sounding out ultrasounds; name game; geek gathering
A tie between first-trimester ultrasounds and autism severity is tenuous at best, misnamed genes litter the literature, and neuroscientists enjoy their version of summer camp.
Sounding out ultrasounds; name game; geek gathering
By
Robin Lloyd
9 September 2016 | 5 min read
Calming remedies; labor lessons; women wanted
New drugs target the brain’s calming chemical, inducing labor does not boost autism risk, and the start is imminent for a project to develop personalized treatments.
Fake facilitation; third strike; Pokémon passion
An autism researcher retracts her third paper in as many years, scientists write fraudulent reviews of their own papers, and Pokémon Go boosts social skills in children with autism.
Brexit break-ups; little impact; micro medicine
Scientists are excluding U.K. colleagues from studies; a life sciences publisher abandons the ‘impact factor;’ and a new open-access journal makes its debut.
CRISPR medicine; inclusive experiments; autism in Egypt
Scientists target human cancer with CRISPR, device trials may become more diverse, and autism awareness grows in Egypt.
CRISPR medicine; inclusive experiments; autism in Egypt
By
Robin Lloyd
24 June 2016 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read